Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging

HPB

Volumn 18, Issue 3, 2016, Pages 296-303

  Owen, Joseph W ^a   Fowler, Kathryn J ^b   Doyle, Maria B ^b   Saad, Nael E ^b   Linehan, David C ^c   Chapman, William C ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GADOXETIC ACID; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; COMPLETE PATHOLOGIC RESPONSE; CONTRAST ENHANCEMENT; DISAPPEARING LESION; DISEASE FREE SURVIVAL; FATTY LIVER; FEMALE; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HEPATOBILIARY MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER RESECTION; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VIABILITY; ADJUVANT CHEMOTHERAPY; CELL SURVIVAL; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NEOADJUVANT THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GADOLINIUM DTPA; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84976416470     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1016/j.hpb.2015.10.009     Document Type: Article

References (17)

1. 1 Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011 Mar), 69–90.
2. 2 Weiss, L., Grundmann, E., Torhorst, J., Hartveit, F., Moberg, I., Eder, M., et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150 (1986 Nov), 195–203.
3. 3 Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000 Sep 28), 905–914.
4. 4 De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 18 (2000 Aug), 2938–2947.
5. 5 Wei, A.C., Greig, P.D., Grant, D., Taylor, B., Langer, B., Gallinger, S., Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13 (2006 May), 668–676.
6. 6 Elias, D., Youssef, O., Sideris, L., Dromain, C., Baton, O., Boige, V., et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86 (2004 Apr 1), 4–9.
7. 7 Benoist, S., Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24 (2006 Aug 20), 3939–3945.
8. 8 Auer, R.C., White, R.R., Kemeny, N.E., Schwartz, L.H., Shia, J., Blumgart, L.H., et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116 (2010 Mar 15), 1502–1509.
9. 9 Elias, D., Goere, D., Boige, V., Kohneh-Sharhi, N., Malka, D., Tomasic, G., et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 14 (2007 Oct 15), 3188–3194.
10. 10 Tan, M.C.B., Linehan, D.C., Hawkins, W.G., Siegel, B.A., Strasberg, S.M., Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11 (2007 Aug 22), 1112–1119.
11. 11 Tanaka, K., Takakura, H., Takeda, K., Matsuo, K., Nagano, Y., Endo, I., Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 250 (2009 Dec), 935–942.
12. 12 Ferrero, A., Langella, S., Russolillo, N., Vigano', L., Lo Tesoriere, R., Capussotti, L., Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg 16 (2012 Apr), 806–814.
13. 13 Van Vledder, M.G., de Jong, M.C., Pawlik, T.M., Schulick, R.D., Diaz, L.A., Choti, M.A., Disappearing colorectal liver metastases after chemotherapy: should we be concerned?. J Gastrointest Surg 14 (2010 Nov), 1691–1700.
14. 14 Bischof, D.A., Clary, B.M., Maithel, S.K., Pawlik, T.M., Surgical management of disappearing colorectal liver metastases: disappearing colorectal liver metastasis. Br J Surg 100 (2013 Oct), 1414–1420.
15. 15 Löwenthal, D., Zeile, M., Lim, W.Y., Wybranski, C., Fischbach, F., Wieners, G., et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 21 (2011 Apr), 832–840.
16. 16 Scharitzer, M., Ba-Ssalamah, A., Ringl, H., Kölblinger, C., Grünberger, T., Weber, M., et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 23 (2013 Aug), 2187–2196.
17. 17 Bendell, J.C., Bekaii-Saab, T.S., Cohn, A.L., Hurwitz, H.I., Kozloff, M., Tezcan, H., et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 17 (2012 Dec 1), 1486–1495.